Type 2 Diabetes Mellitus. Dieser Artikel ist nicht verfügbar.Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus: Exploring Immunogenetic Pathways is a novel reference to gain a deep understanding of the genetic underpinnings and immune system dynamics in Type 2 Diabetes Mellitus (T2DM). It addresses a fundamental gap in the current literature by synthesizing complex information into accessible chapters serving as a roadmap for those needing to navigate the intricate landscape of immunogenetics. It equips readers with the tools to comprehend the underlying mechanisms, discover potential therapeutic strategies, and contribute to the ongoing dialogue in this rapidly advancing field. Real-world case studies and clinical scenarios are throughout the book to illustrate the practical applications of immunogenetics in diagnosing, treating, and managing Type 2 Diabetes Mellitus to help bridge the gap between theory and practice and enhance the relevance of the content for healthcare professionals. The book Explore the integration of multi-omics approaches, including genomics, transcriptomics, proteomics, and metabolomics, to provide a comprehensive understanding of the complex interactions between genetic and immunological factors in Type 2 Diabetes Mellitus. This holistic approach can offer insights into novel biomarkers and therapeutic targets. In addition, discussions on the ethical, legal, and social implications of immunogenetics research in Type 2 Diabetes Mellitus, such as genetic privacy, informed consent, and equity in healthcare access. Addressing these considerations is essential for promoting responsible research practices and ensuring equitable healthcare outcomes. The book is essential for seasoned researchers in T2DM, healthcare professionals, or a student entering the field; this book offers invaluable insights into the future of T2DM research and treatment.

Dr. Hammid Bashir, PhD is a laboratory specialist and biochemist at the Government Medical College since 2012. His research background is in biochemistry and has extensive experience specifically in researching Type 2 Diabetes Mellitus and has a deep understanding of the subject matter. He has published ~49 articles in journals and is a co-editor of three recently published books. He is a rising researcher focused on this field of medicine including Thyroid Diseases, Diabetes and Insulin Resistance.

Shafat Ali (Ph.D.) pursued his BSc. from University of Kashmir and Masters in Zoology from Barkatullah Vishwavidyalaya, India. Currently he is engaged in research work for last 5 years at Cytogenetics and Molecular Biology Laboratory, Centre of Research for Development, University of Kashmir, Department of Biochemistry, Government Medical College, Srinagar, Jammu and Kashmir, and ICMR funded Multidisciplinary Research Unit, Government Medical College, Srinagar, Jammu and Kashmir, India, with specialization in the field of reproductive immunogenetics, cytokine biology, gynaecology and obstetrics, molecular biology, cancer biology and cytogenetics. He has 5 years of research experience and 5 years of teaching experience. He has more than 20 book chapters, several edited books and numerous peer-reviewed, international research publications to his credit. Dr. Ali is also the reviewer of many reputed international journals. Presently, Dr. Ali is involved in studying immunogenetic mechanisms involved in recurrent pregnancy loss.

Dr. Yahya F. Jamous is a Saudi pharmaceutical scientist and Associate Research Professor at Institute of Health Technologies and Preventative Medicine, Health Sector, King Abdulaziz City of Science and Technology (KACST), Riyadh. He has been in the research and teaching field of over 15 years has an excellent history of scientific publications in pharmaceutical biotechnology, nanotechnology, and molecular pharmacology.

Dr. Jamous has served KACST in various high-ranking academic and administrative roles, such as Associate Research Professor, Assistant Research Professor, Acting Director of National Partnerships, and a former Director of the National Vaccines and Bioprocessing Centre (NVBC) in support of programs that go in line with Saudi Vision 2030.

He has a PhD in Molecular Pharmacology at ETH Zurich in new therapeutic targets in heart failure and MSc and BSc degrees in Pharmaceutical Sciences at King Saud University. Dr. Jamous is a licensed Consultant of Pharmaceutical Sciences.